news

Our latest
Press Releases & Updates

Latest press releases

Joint Initiative to Precisely Target Patient Selection for PBM Therapy in Intermediate, Dry AMD Using RetinAI’s Discovery Platform

Discover how RetinAI's groundbreaking Discovery® platform and Gutblick's clinical expertise are joining forces to transform the future of eye care. Their collaboration focuses on harnessing AI technology for advanced research and clinical applications in managing Dry Age-related Macular Degeneration. This partnership signifies a leap forward in personalized treatment and care, setting new standards in ophthalmology.
read more

RetinAI Announces Strategic Partnership with Eyestem to Innovate Geographic Atrophy Clinical Research Using State-of-the-Art AI Technology

read more

RetinAI and Retina Consultants of America Join Forces to build the Most Comprehensive U.S.-based Real World Evidence Database in Ophthalmology

RetinAI Medical AG and Retina Consultants of America (RCA) forge a strategic partnership to revolutionize Ophthalmology data. Leveraging RetinAI's advanced AI technologies and RCA's expansive clinic network, this alliance is set to develop the largest Real World Evidence (RWE) U.S.-based database in the field.
read more

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

RetinAI Medical AG has announced a partnership with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA). RetinAI's AI tools for identifying novel biomarkers will be used to analyze Boehringer Ingelheim's imaging datasets from clinical studies and real-world evidence to identify additional biomarkers and predictors of disease progression. This partnership aims to accelerate the development of novel treatments and enable earlier and more precise diagnosis, contributing to Boehringer Ingelheim's vision of preventing vision loss and blindness caused by retinal diseases.
read more

Latest updates

RetinAI in RTS- Swiss television

The last week of August we received the Swiss Television (SRF - Schweizer Radio und Fernsehen) at our offices in Bern.We talked for a few minutes about what we do and how artificial intelligence is going to change ophthalmology and healthcare in the near future!
‍
Watch it here

Arvo 2019 - Vancouver [MAY’19]

RetinAI had a great conference at this year at ARVO 2019, with more than 15’000 attendees from all over the world!Congratulations to the team for these amazing 5 days of work and for the success on the official release of our two main products: OmniViewer and RetinAI Discovery.

Democratising Access to Health Care - INVESTIERE [APRIL’19]

"Automation does not replace jobs, it replaces tasks" - Learn how RetinAI applies machine learning to medical imaging, not to replace eye doctors, but to make their work less tedious. Via Investiere Venture Capital - Read more

RetinAI in FORBES FR [DECEMBER’18]

RetinAI is honoured to be in December's edition of Forbes France! Artificial Intelligence is changing the world of ophthalmology by democratising access to high-quality eye-care for everyone. Discover a bit more about the future of healthcare in 2019, starting with your eyes! [FR]

‍

Contact us for more informations! We are happy to hear from you!

Contact Us

Ikerian AG (HQ)
‍Freiburgstrasse 3
3010 Bern
Switzerland
‍

RetinAI US Inc. (US)
6 Liberty Square
#2498 Boston, MA 02109
United States

Certifications
SolutionS For
Life Sciences & Pharma
Clinics & Hospitals
Device Manufacturers
Products
DISCOVERY
- UNITY
- For Clinical Studies
- For Clinics
REAL WORLD EVIDENCE
APPS FOR CLINICS
PRECISION MEDICINE
Contact
info@retinai.com
Media kit
Careers
Product User Manual

Imprint/Legal Notice  |  Data Processing Agreement  |  Privacy Notice  |  Created by Ikerian AG. All rights reserved 2016-2025 ©